103 related articles for article (PubMed ID: 23162075)
1. Genetically engineered fusion proteins for treatment of cancer.
Weidle UH; Schneider B; Georges G; Brinkmann U
Cancer Genomics Proteomics; 2012 Nov; 9(6):357-72. PubMed ID: 23162075
[TBL] [Abstract][Full Text] [Related]
2. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
Khawli LA; Hu P; Epstein AL
Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
[TBL] [Abstract][Full Text] [Related]
3. Targeting cytokines to tumors to induce active antitumor immune responses by recombinant fusion proteins.
Xiang J
Hum Antibodies; 1999; 9(1):23-36. PubMed ID: 10331183
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo activities of OX40 (CD134)-IgG fusion protein isoforms with different levels of immune-effector functions.
Taylor L; Bachler M; Duncan I; Keen S; Fallon R; Mair C; McDonald TT; Schwarz H
J Leukoc Biol; 2002 Sep; 72(3):522-9. PubMed ID: 12223520
[TBL] [Abstract][Full Text] [Related]
5. Antibody-IL-2 fusion proteins: a novel strategy for immune protection.
Penichet ML; Harvill ET; Morrison SL
Hum Antibodies; 1997; 8(3):106-18. PubMed ID: 9322080
[TBL] [Abstract][Full Text] [Related]
6. Binding of divalent H-2Kd/IgG2aFc fusion protein to murine macrophage via Fc-FcR interaction.
Xiao W; Chen X; Lin Zhou ; Lu S; Liang Z; Wu X
Cell Mol Immunol; 2007 Apr; 4(2):147-51. PubMed ID: 17571461
[TBL] [Abstract][Full Text] [Related]
7. Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune response.
Hombach A; Hombach AA; Abken H
Gene Ther; 2010 Oct; 17(10):1206-13. PubMed ID: 20555360
[TBL] [Abstract][Full Text] [Related]
8. Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells.
Xu XJ; Tang YM
Cancer Lett; 2014 Feb; 343(2):172-8. PubMed ID: 24141191
[TBL] [Abstract][Full Text] [Related]
9. Novel TGF-beta antagonist inhibits tumor growth and angiogenesis by inducing IL-2 receptor-driven STAT1 activation.
Penafuerte C; Bautista-Lopez N; Bouchentouf M; Birman E; Forner K; Galipeau J
J Immunol; 2011 Jun; 186(12):6933-44. PubMed ID: 21551368
[TBL] [Abstract][Full Text] [Related]
10. Horse cytokine/IgG fusion proteins--mammalian expression of biologically active cytokines and a system to verify antibody specificity to equine cytokines.
Wagner B; Robeson J; McCracken M; Wattrang E; Antczak DF
Vet Immunol Immunopathol; 2005 May; 105(1-2):1-14. PubMed ID: 15797470
[TBL] [Abstract][Full Text] [Related]
11. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
Repp R; Kellner C; Muskulus A; Staudinger M; Nodehi SM; Glorius P; Akramiene D; Dechant M; Fey GH; van Berkel PH; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
J Immunol Methods; 2011 Oct; 373(1-2):67-78. PubMed ID: 21855548
[TBL] [Abstract][Full Text] [Related]
12. B7.1/NHS76: a new costimulator fusion protein for the immunotherapy of solid tumors.
Liu A; Hu P; Khawli LA; Epstein AL
J Immunother; 2006; 29(4):425-35. PubMed ID: 16799338
[TBL] [Abstract][Full Text] [Related]
13. Direct detection and quantitation of a distinct T-cell epitope derived from tumor-specific epithelial cell-associated mucin using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells.
Cohen CJ; Hoffmann N; Farago M; Hoogenboom HR; Eisenbach L; Reiter Y
Cancer Res; 2002 Oct; 62(20):5835-44. PubMed ID: 12384546
[TBL] [Abstract][Full Text] [Related]
14. Carcinoembryonic antigen-immunoglobulin Fc fusion protein (CEA-Fc) for identification and activation of anti-CEA immunoglobulin-T-cell receptor-modified T cells, representative of a new class of Ig fusion proteins.
Ma Q; DeMarte L; Wang Y; Stanners CP; Junghans RP
Cancer Gene Ther; 2004 Apr; 11(4):297-306. PubMed ID: 15002034
[TBL] [Abstract][Full Text] [Related]
15. Conversion of a tumor-binding peptide identified by phage display to a functional chimeric T cell antigen receptor.
Pameijer CR; Navanjo A; Meechoovet B; Wagner JR; Aguilar B; Wright CL; Chang WC; Brown CE; Jensen MC
Cancer Gene Ther; 2007 Jan; 14(1):91-7. PubMed ID: 17024231
[TBL] [Abstract][Full Text] [Related]
16. Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ.
Takayama K; Ueno H; Nakanishi Y; Sakamoto T; Inoue K; Shimizu K; Oohashi H; Hara N
Cancer Res; 2000 Apr; 60(8):2169-77. PubMed ID: 10786681
[TBL] [Abstract][Full Text] [Related]
17. Functional design of chimeric T-cell antigen receptors for adoptive immunotherapy of cancer: architecture and outcomes.
Shirasu N; Kuroki M
Anticancer Res; 2012 Jun; 32(6):2377-83. PubMed ID: 22641678
[TBL] [Abstract][Full Text] [Related]
18. The targeted delivery of IL17 to the mouse tumor neo-vasculature enhances angiogenesis but does not reduce tumor growth rate.
Pasche N; Frey K; Neri D
Angiogenesis; 2012 Mar; 15(1):165-9. PubMed ID: 22052195
[TBL] [Abstract][Full Text] [Related]
19. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis factor receptor-IgG fusion protein for targeted drug delivery across the human blood-brain barrier.
Hui EK; Boado RJ; Pardridge WM
Mol Pharm; 2009; 6(5):1536-43. PubMed ID: 19624167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
